PRQR Stock — ProQR Therapeutics N.V.

Up next

FQ3-26 quarter ends

~Sep 30, 2026 Est

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Limited Quant / Vol Very High

Market backdrop VIX 14.4 · calm Equity put/call 0.62

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +28%

above

Price vs 50-day avg +22%

above

RSI (14) 65

neutral

MACD trend Positive

52-week position 55%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Strong

1-month return +33%

trailing

6-month return +21%

trailing

YTD return +13%

this year

Relative strength +8%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $2 › 200d $2 — 50d above 200d

Institutional flow Flat

0% holders QoQ · +12 funds added

Insider flow Accumulating

Net +$1.3M over 90 days · 0% sells

Short interest Rising

1.58% of float · ▲ +0.2% MoM · 3.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

69 holders — mid 3-yr range

Squeeze score 62

elevated · 0–100

Fundamentals

Limited

Not enough data for a confident read.

Quant / Vol

risk profile

Very High

Volatility 77%

annualized · 1-yr

Max drawdown −55%

past year

ATR 6.0%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy

0 · 4 · 3

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+28% Bullish

Price vs 50-day avg

+22% Bullish

RSI (14)

65 Neutral

MACD trend

Positive Bullish

52-week position

55% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $2 › 200d $2 — 50d above 200d

Institutional flow Flat

0% holders QoQ · +12 funds added

Insider flow Accumulating

Net +$1.3M over 90 days · 0% sells

Short interest Rising

1.58% of float · ▲ +0.2% MoM · 3.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

69 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $1 Now $2 · 55% Range high $3

vs 200-day avg +28% vs 50-day avg +22%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
PRQR ProQR Therapeutics N.V. this stock	$328.38M	+13.4%	—	—	1.6%
VRTX Vertex Pharmaceuticals Inc / Ma	$137.30B	+19.5%	+46.2%	31.6	1.6%
REGN Regeneron Pharmaceuticals, Inc.	$81.27B	+2.9%	+20.8%	19.6	2.3%
ARGX Argenx SE	$63.63B	+21.7%	—	—	1.9%
CSLLY Csl Ltd	$59.92B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

69

% held: 42.9%
Net QoQ: +25.5M sh
Top holder: ADAGE CAPITAL PARTNERS GP…

Held Float

View

Held by Funds

Fund positions

2

View

Short & Settlement

Short Interest Rising

Shares short

2.2M

Days to cover: 3.0d
Change: +4.9K sh

View

Short Volume

Short vol %

50%

As of: Aug 28, 2026

Short Total

View

Fails to Deliver

FTD shares

1.7K

Value: $3.0K
As of: Jul 30, 2026

View

Off-Exchange

Off-exchange %

38.1%

Week of: Jul 20, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net buying

Net (90d)

+$1.3M

Buyers / Sellers: 2 / 0

Buyers Sellers

View

Filings

SEC Filings

Latest

6-K

Filed: Aug 13, 2026
This year: 16

View

	5D	20D	120D	MTD	YTD
PRQR	-2.1%	+33.1%	+21.2%	+33.1%	+13.4%
SPY	+0.5%	+3.0%	+13.4%	+3.0%	+12.8%
vs SPY	-2.6%	+30.2%	+7.7%	+30.2%	+0.6%

PRQR · ProQR Therapeutics N.V.

Price & Indicators

Up next

Equibles Rating

Technicals

Versus peers

At a glance

Performance